ArticleScientific reports2016
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis.Scientific reports · 2020Trial
- Increased expression of OX40 on peripheral CD4Acta diabetologica · 2026Article
- Second-order regulation: IFN-γ suppresses IL-17A-mediated type 3 inflammation.Frontiers in immunology · 2026Article
- CD56 on immune and tumor cells: what is known and beyond?Clinical and experimental immunology · 2025Review
- Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.Clinical and experimental immunology · 2024Article
- An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.Expert opinion on pharmacotherapy · 2023Review
- Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune-driven demyelination.Clinical & translational immunology · 2023Article
- T cells from MS Patients with High Disease Severity Are Insensitive to an Immune-Suppressive Effect of Sulfatide.Molecular neurobiology · 2022Article
- Contact-Dependent Granzyme B-Mediated Cytotoxicity of Th17-Polarized Cells Toward Human Oligodendrocytes.Frontiers in immunology · 2022Article
- Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.Frontiers in immunology · 2022Article
- Tetracyclines DiminishFrontiers in immunology · 2021Article
- Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.Journal of neuroimmunology · 2020Article
- Memory CD4Cells · 2020Review
- Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.Journal of autoimmunity · 2019Article
- NF-κB/mTOR/MYC Axis Drives PRMT5 Protein Induction After T Cell Activation via Transcriptional and Non-transcriptional Mechanisms.Frontiers in immunology · 2019Article
- Regulation of lymphocyte trafficking in central nervous system autoimmunity.Current opinion in immunology · 2018Review
- Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis.Brain sciences · 2017Review
- Neurological safety of fingolimod: An updated review.Clinical & experimental neuroimmunology · 2017Review
- CD56 in the Immune System: More Than a Marker for Cytotoxicity?Frontiers in immunology · 2017Review
- Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a T cell-mediated autoimmune disease. Fingolimod, a highly effective disease-modifying drug for MS, retains CCR7
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.